HomeQuestion

Would you consider the addition of immunotherapy to chemo for unresectable epithelioid mesothelioma based on the phase 2 PrE0505 and DREAM trial?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

In light of data from TRIANGLE, ECHO, and ENRICH, what is the best strategy to treat newly diagnosed patients with the blastoid variant MCL?

How would you manage a patient with a recent diagnosis of advanced DLBCL (non-GCB subtype) who has baseline grade 3 neuropathy?

Do you still recommend consolidative allogeneic stem cell transplants for patients with Richter transformation in CR after frontline treatment in the modern era of therapies?

If you are using talquetamab as bridging before BCMA CAR-T therapy, when do you assess for response and/or stop the talquetamab?

After the MAJESTEC-3 results, what is your approach to choosing between tec-dara vs. cilta-cel versus another triplet for multiple myeloma in first relapse?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.